These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 7018668

  • 1. Adoptive therapy of established syngeneic leukemia by cells primarily sensitized in vitro.
    Cheever MA, Greenberg PD, Fefer A.
    Cancer Res; 1981 Jul; 41(7):2658-63. PubMed ID: 7018668
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens.
    Cohen P, Vourka-Karussis U, Weiss L, Slavin S.
    J Immunol; 1993 Nov 01; 151(9):4803-10. PubMed ID: 8409438
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Occurrence of tumor antigen pRL1a specific CD8 T cells in spleen cells from syngeneic BALB/c, semiallogeneic (BALB/c x C57BL/6)F1 and allogeneic C57BL/6 mice.
    Hata H, Uenaka A, Takada I, Kenjo A, Takahashi M, Ono T, Fujita T, Nakayama E.
    Int J Oncol; 2002 May 01; 20(5):1019-25. PubMed ID: 11956599
    [Abstract] [Full Text] [Related]

  • 10. Tumor sponge implantation: an in vivo method for studying syngeneic, primary antitumor lymphocyte responses.
    Vallera DA, Mentzer SJ, Maizel SE.
    Cancer Res; 1982 Feb 01; 42(2):397-404. PubMed ID: 7055792
    [Abstract] [Full Text] [Related]

  • 11. Suppression of the in vitro secondary response to syngeneic tumor and of in vivo tumor therapy with immune cells by culture-induced suppressor cells.
    Greenberg PD, Cheever M, Fefer A.
    J Immunol; 1979 Aug 01; 123(2):515-22. PubMed ID: 222839
    [Abstract] [Full Text] [Related]

  • 12. Suppression of secondary cellular immunity to a tumor allograft by cyclophosphamide and 1,3-bis(2-chloroethyl)-1-nitrosourea.
    Einstein AB, Fass L, Fefer A.
    Cancer Res; 1975 Mar 01; 35(3):492-6. PubMed ID: 1078784
    [Abstract] [Full Text] [Related]

  • 13. Drug-mediated immunogenic changes of virus-induced leukemia in vivo.
    Houchens DP, Bonmassar E, Gaston MR, Kende M, Goldin A.
    Cancer Res; 1976 Apr 01; 36(4):1347-52. PubMed ID: 1260759
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Immunogenicity of tumor cells modified by trinitrobenzene suflonic acid (TNBS).
    Kedar E, Unger E, Galili N, Klein G, Asjo B, Bonavida B, Naor D.
    Prog Clin Biol Res; 1976 Apr 01; 9():109-21. PubMed ID: 1030796
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cyclophosphamide-induced appearance of immunopotentiating T-cells in the spleens of mice bearing a large MOPC-315 tumor.
    Ye QW, Mokyr MB.
    Cancer Res; 1984 Sep 01; 44(9):3873-9. PubMed ID: 6611201
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.